Search Results

· VIAL-TL1A-HLE is a novel, subcutaneous mAb with proprietary half-life extension technology targeting TL1A for a potentially best-in-class treatment for IBD · Preclinical data support the potential for best-in-class dosing interval for patient convenience and efficacy among anti-TL1A therapies · A Phase 1 open-label study in Australia is initiating to evaluate safety, pharmacokinetics, and pharmacodynamic responses in healthy volunteers · Interim subcutaneous safety and pharmacokinetic data from healthy volunteers expected in H2 2025

Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.

Later this month, HHS Secretary Robert F. Kennedy Jr.'s revamped CDC vaccine advisory committee will discuss RSV vaccination guidelines for the newly approved patient group, high-risk adults 18 through 49. Analysts and other experts have warned that the new panel includes some who have documented anti-vaccine sentiments as well as those who have spoken out against mRNA technology specifically.

Friday’s deal with CSPC fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.